• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

英国罕见病用药纳入报销体系的主要途径及对我国的启示

袁妮, 田婷婷, 张海军, 王勇

袁妮, 田婷婷, 张海军, 王勇. 英国罕见病用药纳入报销体系的主要途径及对我国的启示[J]. 中国药科大学学报, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
引用本文: 袁妮, 田婷婷, 张海军, 王勇. 英国罕见病用药纳入报销体系的主要途径及对我国的启示[J]. 中国药科大学学报, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
shu
YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
Citation: YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
shu

英国罕见病用药纳入报销体系的主要途径及对我国的启示

  • 1.

    中国药科大学国际医药商学院

  • 2.

    大连医科大学公共卫生学院

Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China

摘要

    摘要
  • 摘要: 为我国建立合理且多元化的罕见病用药纳入报销体系制度提供经验及启示，本研究通过查阅英国国家卫生与临床优化研究所(National Institute for Health and Care Excellence，NICE)与英国国民健康保障体系(National Health Service，NHS)官网，收集英国有关罕见病用药纳入报销体系的资料，归纳并分析相关文献，对罕见病患者药品的可及性进行理论研究。在NHS体系中，英国罕见病用药纳入报销体系主要可以通过7种途径:由NICE负责评估的3种途径(多技术评估MTA、单一技术评估STA、高度专业化技术评估HST)与NHS直接管理的4种途径(专项购买服务、肿瘤药物基金CDF、个人资金申请IFRs、对缺乏临床数据项目的评估购买计划CtE)。通过分析英国罕见病用药纳入报销体系的7种主要途径及英国在实施多种纳入报销途径中出现的问题，对我国罕见病用药的报销制度的建立有一定借鉴意义。
    Abstract: In order to provide enlightening experience for the establishment of reasonable and diversified orphan drugs into the reimbursement system in China, the official websites of the National Institute for Health and Care Excellence(NICE)and the National Health Service(NHS)in the UK were inspected, collecting and summarizing the relevant documents, on the inclusion of orphan drugs into the reimbursement system. Relevant literatures were analyzed with theoretical studies on the accessibility of medicines for patients with rare diseases. In the NHS system, the inclusion of orphan drugs into the reimbursement system in the UK can be achieved mainly through seven routes, with three routes that are evaluated by NICE(MTA, STA and HST)and four are directly managed by the NHS(specialized commissioning, CDF, IFRs, CtE). Through the analysis of the inclusion of orphan drugs into the reimbursement system and the various problems in the UK, we have found some enlightening experience for the establishment of the reimbursement system for orphan drugs in China.
    • HTML全文
    • 参考文献(17)
  • [1] Gong SW.Study of management strategies of improving access to orphan drugs in china(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [2] Sui BY,Qi XR.Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J].Chin J Health Policy(中国卫生政策研究),2015,8(7):74-78.
    [3] National Institute for Health and Care Excellence.Guide to the processes of technology appraisal2014[R].London:NICE,2014.
    [4] National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-03-19] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice technology-appraisal-guidance/summary-of-decisions.
    [5] National Institute for Health and Care Excellence.Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease[R].London:NICE,2017.
    [6] National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-05-17] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions.
    [7] National Institute for Health and Care Excellence.Guide to the processes of technology appraisal 2014[R].London:NICE,2014.
    [8] National Institute for Health and Care Excellence.Eltrombopag for treating chronic immune(idiopathic)thrombocytopenic purpura[R].London:NICE,2013.
    [9] National Institute for Health and Care Excellence.Interim process and methods of the highly specialized technologies programme[R].London:NICE,2017.
    [10] National Health Service.Specialized services[EB/OL].[2018-05-18] .https://www.england.nhs.uk/commissioning/spec-services/.
    [11] NHS England.Implementation plan for the uk strategy for rare diseases[R].England:NHS England,2018.
    [12] NHS England Cancer Drugs Fund Team.Appraisal and funding of cancer drugs from July 2016(including the new Cancer Drugs Fund)- A new deal for patients,taxpayers and industry[R].England:NHS England,2016.
    [13] NHS England Cancer Drugs Fund Team.National cancer drugs fund list[R].England:NHS England,2016.
    [14] National Institute for Health and Care Excellence.Consultation comments on the draft remit and draft scope for the technology appraisal of cabozantinib for previously treated advanced renal cell carcinoma[R].England:NICE.
    [15] Specialized Commissioning Team.Standard operating procedures:individual funding requests[R].England:NHS England,2017.
    [16] NHS England.Methods:Commissioning through Evaluation[R].England:NHS England,2017.
    [17] National Health Service.Commissioning through evaluation[EB/OL].[2018-05-20] .https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/.
    • 相关文章
    • 施引文献(13)

  • 期刊类型引用(10)

    1. 张奇林，庞昕，马黎黎. 全球视域下罕见病用药可及性管理的比较分析与经验借鉴. 中国新药杂志. 2025(02): 123-129 . 百度学术
    2. 杨伊凡，谢金平，闫丽羽，翁婷婷，邵蓉. 欧洲典型国家孤儿药定价和报销策略分析及对我国的启示. 中国卫生经济. 2024(02): 92-96 . 百度学术
    3. 陈昕阳，陈烨，丁锦希. 罕见病用药多层次医疗保障体系的构建与优化. 世界临床药物. 2024(11): 1132-1140 . 百度学术
    4. 邓韬毅，刘德阳，周静，武志昂，胡明. 英国罕见病用药医保准入政策分析及对我国的启示. 中国药房. 2023(13): 1555-1561 . 百度学术
    5. 郭小会，袁雪丹. 基于救援规则的罕见病用药评价指标初探. 中国医疗保险. 2023(07): 97-103 . 百度学术
    6. 曹颖，王森，邹锟，徐小军. 罕见病用药医保现状分析及思考. 赣南医学院学报. 2023(06): 620-625+636 . 百度学术
    7. 张晔，王翔宇. 从罕见病行业发展看医药企业社会责任及政府激励作用. 医学与哲学. 2021(04): 9-14 . 百度学术
    8. 袁妮，周娜，杨勇，宋海，王勇. 英国罕见病药物准入过程中价格谈判机制的实施经验及启示. 中国新药杂志. 2020(05): 481-486 . 百度学术
    9. 陈馨仪，符晓，王安石，李春生，张滨. 罕见病患者治疗及保障研究. 卫生经济研究. 2020(09): 40-42+46 . 百度学术
    10. 谢金平，邵蓉. 英国NICE药品卫生技术评估和决策框架体系研究及启示. 中国卫生经济. 2020(12): 114-119 . 百度学术

    其他类型引用(3)

    • 资源附件(0)
计量
  • 文章访问数:  844
  • HTML全文浏览量:  7
  • PDF下载量:  1564
  • 被引次数: 13
出版历程
  • 刊出日期:  2019-02-24

目录

摘要
HTML全文
    参考文献(17)
    相关文章
    施引文献(13)
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：414195